Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders (2010 - 2026)

Acadia Pharmaceuticals' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 80.84% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $375.6 million, a 64.12% increase from a year earlier, with the FY2025 full-year figure at $391.0 million, up 72.66% from the prior year.
• Net Income towards Common Stockholders eased to $3.6 million in Q1 2026 per ACAD's latest filing, from $273.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $273.6 million in Q4 2025 and bottomed at -$113.1 million in Q1 2022.
• The 5-year median for Net Income towards Common Stockholders is $16.6 million (2024), against an average of $20.2 million.
• Across the five-year window, Net Income towards Common Stockholders sank 139.9% in 2023 and soared 2897.22% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$41.6 million in 2022, then jumped by 209.97% to $45.8 million in 2023, then jumped by 213.87% to $143.7 million in 2024, then surged by 90.32% to $273.6 million in 2025, then plunged by 98.67% to $3.6 million in 2026.
• Per Business Quant, the three latest ACAD Net Income towards Common Stockholders figures stand at $3.6 million (Q1 2026), $273.6 million (Q4 2025), and $71.8 million (Q3 2025).